Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The goal of this study to find the highest tolerable dose of sapacitabine that can be given
to patients with advanced leukemias or myelodysplastic syndromes.